"De locatie Erasmus MC-Daniel den Hoed bestaat niet meer. De patiëntenzorg is verhuisd naar Erasmus MC, Dr. Molewaterplein 40, 3015 GD Rotterdam."

During the past decade, Erasmus MC Cancer Institute conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 1 clinical trials were completed, i.e. on average, 6.7% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 1 clinical trials were completed. i.e. 20% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Erasmus MC Cancer Institute" #1 sponsor was "The Netherlands Cancer Institute" with 4 trials, followed by "Erasmus Medical Center" with 2 trials sponsored, "Incyte Corporation" with 2 trials sponsored, "Blueprint Medicines Corporation" with 1 trials sponsored and "Catharina Ziekenhuis Eindhoven" with 1 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Erasmus MC Cancer Institute" #1 collaborator was "AbbVie" with 1 trials as a collaborator, "Bayer" with 1 trials as a collaborator, "Catharina Ziekenhuis Eindhoven" with 1 trials as a collaborator, "Centre for Human Drug Research, Netherlands" with 1 trials as a collaborator and "Erasmus Medical Center" with 1 trials as a collaborator. Other collaborators include 3 different institutions and companies that were collaborators in the rest 13 trials.

According to Clinical.Site data, the most researched conditions in "Erasmus MC Cancer Institute" are "Breast Cancer" (3 trials), "Advanced Solid Tumors" (2 trials), "Adult-type Diffuse Gliomas" (1 trials), "Colon Cancer" (1 trials) and "Colorectal Cancer" (1 trials). Many other conditions were trialed in "Erasmus MC Cancer Institute" in a lesser frequency.

Most popular intervention types in "Erasmus MC Cancer Institute" are "Drug" (13 trials), "Biological" (1 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (1 trials), "Avapritinib" (1 trials), "Carboplatin" (1 trials), "Dacomitinib" (1 trials) and "Docetaxel" (1 trials). Other intervention names were less common.

The vast majority of trials in "Erasmus MC Cancer Institute" are 13 trials for "All" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Erasmus MC Cancer Institute". 1 are not yet recruiting, 6 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Erasmus MC Cancer Institute, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Erasmus MC Cancer Institute, 7 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".